Two of the world’s biggest drugmakers just teamed up on a coronavirus vaccine
Two of the world’s largest drugmakers are now working together to develop a coronavirus vaccine.
Sanofi and GlaxoSmithKline announced the collaboration Tuesday morning. They aim to start testing a potential vaccine in humans later this year to be ready for use in the second half of 2021. Financial terms of the deal weren’t disclosed.
The two European pharmas each bring decades of experience in vaccine development. Their combined market value exceeds $200 billion and they employ roughly 200,000 workers.
Sanofi will use an antigen targeting the coronavirus’ signature spike protein, and GSK will provide an adjuvant, which can reduce the amount of vaccine needed per dose. The US Biomedical Advanced Research and Development Authority (BARDA) has partially funded Sanofi’s vaccine research.
BARDA Director Rick Bright said in a statement this collaboration “holds the potential to lower the vaccine dose to provide vaccine to a greater number of people to end this pandemic, and help the world become better prepared or even prevent future coronavirus outbreaks.”
Sanofi and GSK have also established a joint task force bringing together executives at both companies, with the goal of accelerating the vaccine’s development. The two pharma giants stated they “are committed to making any vaccine that is developed through the collaboration affordable to the public.” They said they plan to “offer fair access for people in all countries.”
A sharpening distinction between new- and old-school vaccine approaches
The deal also shows the contrast in approaches between some pharma giants using well-known vaccine technologies versus smaller biotechnology firms that are now applying unproven, novel approaches against the coronavirus.
These biotechs have sped past Big Pharma into clinical testing. Moderna and Inovio Pharmaceuticals have both already started dosing healthy volunteers with their experimental vaccines, which leverage new genetic technologies.
Moderna is testing a messenger RNA (mRNA) vaccine that instructs human cells to produce virus-fighting proteins called antibodies. Inovio developed a DNA vaccine which delivers optimized DNA into cells to spur an immune response.
Both approaches are based on decades of research but have yet to lead to any vaccines approved by the US Food and Drug Administration. Both platforms have the advantage of using only genetic code, instead of requiring samples of the live virus. That helps speed up much of the early-stage development work.
Sanofi and GSK are using a well-established platform of a protein-based vaccine plus an adjuvant. While it will take longer to begin human testing, the companies argue they can quickly progress given the familiarity of this technology.
Sanofi is also working with a tiny Massachusetts biotech called Translate Bio to advance an mRNA coronavirus vaccine. GSK is supplying its adjuvant technology to other vaccine programs from the University of Queensland, the Chinese biotech Clover Biopharmaceuticals, and Xiamen Innovax Biotech.
The big pharmas overshadow smaller biotechs in terms of resources, both in capital on-hand and existing infrastructure. Manufacturing a vaccine in quantities large enough to meet worldwide demand is expected to present a challenge for companies of every size.
GSK and Sanofi did not provide an estimate of their combined production capacity in Tuesday’s release. Sanofi has previously stated it can make hundreds of millions of doses per year of a coronavirus vaccine with its existing production plants.
Source: Business Insider
